Rallybio Shareholders to Hold 3.65% Post-Merger as Law Firm Probes Deal Terms
Halper Sadeh LLC is investigating Rallybio Corporation's proposed merger with Candid Therapeutics, which would leave Rallybio shareholders with about 3.65% ownership of the combined company. The firm may seek increased consideration, additional disclosures, or other relief on a contingent fee basis for shareholders.
1. Merger Overview
Rallybio Corporation has agreed to merge with Candid Therapeutics, with existing Rallybio shareholders slated to own approximately 3.65% of the combined entity upon closing. The terms of the deal include share exchange ratios and governance provisions that define the post-merger ownership structure.
2. Legal Investigation
Investor rights law firm Halper Sadeh LLC has launched an investigation into the merger, examining potential breaches of fiduciary duty and federal securities law violations. The probe focuses on whether insiders receive preferential treatment or if deal terms restrict competing bids.
3. Shareholder Options
Shareholders represented by Halper Sadeh LLC could pursue increased consideration, seek additional deal disclosures, or obtain other relief through litigation. The firm operates on a contingent fee basis, meaning shareholders would incur no out-of-pocket legal expenses unless the firm recovers benefits on their behalf.